Mr. Speaker, I listened with great interest to the member's speech about expediting the approval of medicines or pharmaceutical drugs in the country. I have a friend who just received her Ph.D. at Dalhousie University, lauded as the best Ph.D. of the year. Her analysis was the input of the public into the review of drugs for breast cancer and the difference in the end analysis when organizations were given the opportunity to have input or not. We need merely refer to the issue of Oxycontin and the disaster that resulted when there was no proper review of what its implications might be given the form in which that medicine was allowed to be released.
I am giving the member the opportunity to rethink whether or not it makes sense to always short-circuit and fast-track the approval of drugs.